Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Findings from H.F. Wei and co-authors broaden understanding of cancer vaccines
July 2nd, 2008
According to recent research published in the journal Cancer Research, "Modest clinical outcomes of dendritic cell (DC) vaccine trials call for novel strategies. In this study, we have created a chimeric CD40 molecule that incorporates a single chain Fv (scFv) molecule specific for human ErbB2 antigen and fusing to the membrane spanning and cytosolic domains of murine CD40." "After adenoviral transfer to bone marrow-derived DC, this chimeric receptor (CR) induced nuclear factor-kappa B (NF-kappa B)-dependent DC activation and effector function when cultured with immobilized ErbB2 protein or ErbB2-positive tumor cells in vitro. In vivo migration assays showed that...
Source: Vaccine Weekly (2008-07-02)
|
